| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.08 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.08 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.062 | 0.09 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.064 | 0.09 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.083 | 0.09 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.09 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.09 |